Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transition from natalizumab to fingolimod in relapsing-remitting multiple sclerosis
2011-001442-15Phase 4Terminated
- Sponsor
- Novartis
- Start
- May 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fingolimod and natalizumab in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Novartis. Started May 2011; status: terminated.
02
Drugs
fingolimodnatalizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2011-001442-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001442-15.